Earlier on Monday, Horizon, which mostly deals with gene editing applications, said its half-year core loss before one-off items narrowed from last year. ValueAct Capital has almost doubled its stake in UK life - sciences company Horizon Discovery to just under 10 % with the acquisition of 100 million shares from Woodford Capital Management . In a statement , the activist hedge fund said it was now pondering the appointment of a member of its team to the Horizon board . In response , the Cambridge firm said its board was " very strong , well governed and appropriately constituted " . Horizon recently reported a narrower net loss than expected and estimated full - year revenue would beat consensus .
ValueAct Capital has almost doubled its stake in UK life - sciences company Horizon Discovery to just under 10 % with the acquisition of 100 million shares from Woodford Capital Management . In a statement , the activist hedge fund said it was now pondering the appointment of a member of its team to the Horizon board . In response , the Cambridge firm said its board was " very strong , well governed and appropriately constituted " . Horizon recently reported a narrower net loss than expected and estimated full - year revenue would beat consensus .